Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05398861 | Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer | PHASE2 | RECRUITING | 79 | — | — | Aug 19, 2022 | May 30, 2027 | Apr 16, 2026 | 1 | China |
PFS is defined as the duration of time from first study treatment to disease progression or death from any cause as documented by the investigator
| Arm | Type | Description |
|---|---|---|
| HER-2 Negative Advanced Breast Cancer | EXPERIMENTAL | Utidelone Combined with Bevacizumab |
| Name | Type | Description |
|---|---|---|
| utidelone injection | DRUG | Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days. |
| Bevacizumab | DRUG | Bevacizumab: 10mg/kg, administered on day 1 of each cycle, with a treatment cycle lasting 21 days; |
Inclusion Criteria: 1. Signed Informed Consent Form; 2. Women aged 18-70 years; 3. The number of treatment lines for patients ≥ 2 lines； 4. Histologically or cytologically confirmed HER2-negative locally advanced or metastatic breast cancer: 5. Patients with HER2-negative breast cancer who have fai...